

Docket Numbers: RP25–804–000.
Applicants: Gulf South Pipeline Company, LLC.
Description: § 4(d) Rate Filing: Cap Rel Neg Rate Agmt (Methanex 52142 to Tenaska 59186) to be effective 4/1/2025.
Filed Date: 4/1/25.
Accession Number: 20250401–5404.
Comment Date: 5 p.m. ET 4/14/25.
Docket Numbers: RP25–805–000.
Applicants: Gulf South Pipeline Company, LLC.
Description: § 4(d) Rate Filing: Cap Rel Neg Rate Agmt (Osaka 46429 to Texla 59183) to be effective 4/1/2025.
Filed Date: 4/1/25.
Accession Number: 20250401–5413.
Comment Date: 5 p.m. ET 4/14/25.
Docket Numbers: RP25–806–000.
Applicants: ANR Pipeline Company.
Description: § 4(d) Rate Filing: ANR April 1 NR Agmts to be effective 4/1/2025.
Filed Date: 4/1/25.
Accession Number: 20250401–5424.
Comment Date: 5 p.m. ET 4/14/25.
Docket Numbers: RP25–807–000.
Applicants: Equitrans, L.P.
Description: § 4(d) Rate Filing: Negotiated Rate Capacity Release Agreements—04/01/2025 to be effective 4/1/2025.
Filed Date: 4/1/25.
Accession Number: 20250401–5430.
Comment Date: 5 p.m. ET 4/14/25.
Docket Numbers: RP25–808–000.
Applicants: Gulf South Pipeline Company, LLC.
Description: § 4(d) Rate Filing: Cap Rel Neg Rate Agmts (JERA 46435, 46434 to JERA Americas 58871, 58872) to be effective 4/1/2025.
Filed Date: 4/1/25.
Accession Number: 20250401–5432.
Comment Date: 5 p.m. ET 4/14/25.
Docket Numbers: RP25–809–000.
Applicants: Rockies Express Pipeline LLC.
Description: Compliance filing: REX 2025–04–01 Annual Purchases and Sales Report to be effective N/A.
Filed Date: 4/1/25.
Accession Number: 20250401–5455.
Comment Date: 5 p.m. ET 4/14/25.
Docket Numbers: RP25–810–000.
Applicants: Trailblazer Pipeline Company LLC.
Description: Compliance filing: TPC 2025–04–01 2024 Annual Purchases and Sales Report to be effective N/A.
Filed Date: 4/1/25.

Accession Number: 20250401–5458.
Comment Date: 5 p.m. ET 4/14/25.
Docket Numbers: RP25–811–000.
Applicants: Golden Pass Pipeline LLC.
Description: Compliance filing: Golden Pass Pipeline Revised Tariff Records Re: Order No. 587–AA to be effective 4/1/2025.
Filed Date: 4/2/25.
Accession Number: 20250402–5002.
Comment Date: 5 p.m. ET 4/14/25.
Docket Numbers: RP25–812–000.
Applicants: Rover Pipeline LLC.
Description: § 4(d) Rate Filing: Summary of Negotiated Rate Capacity Release Agreements 4–2–2025 to be effective 4/1/2025.
Filed Date: 4/2/25.
Accession Number: 20250402–5072.
Comment Date: 5 p.m. ET 4/14/25.
 Any person desiring to intervene, to protest, or to answer a complaint in any of the above proceedings must file in accordance with Rules 211, 214, or 206 of the Commission's Regulations (18 CFR 385.211, 385.214, or 385.206) on or before 5:00 p.m. Eastern time on the specified comment date. Protests may be considered, but intervention is necessary to become a party to the proceeding.
 The filings are accessible in the Commission's eLibrary system (<https://elibrary.ferc.gov/idmws/search/fercensearch.asp>) by querying the docket number.
 eFiling is encouraged. More detailed information relating to filing requirements, interventions, protests, service, and qualifying facilities filings can be found at: <http://www.ferc.gov/docs-filing/efiling/filing-req.pdf>. For other information, call (866) 208–3676 (toll free). For TTY, call (202) 502–8659.
 The Commission's Office of Public Participation (OPP) supports meaningful public engagement and participation in Commission proceedings. OPP can help members of the public, including landowners, community organizations, Tribal members and others, access publicly available information and navigate Commission processes. For public inquiries and assistance with making filings such as interventions, comments, or requests for rehearing, the public is encouraged to contact OPP at (202) 502–6595 or OPP@ferc.gov.

Dated: April 2, 2025.
Carlos D. Clay,
Deputy Secretary.
 [FR Doc. 2025–05996 Filed 4–7–25; 8:45 am]
BILLING CODE 6717–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Small Business: Applied Immunology and Vaccine Development.

Date: May 14–20, 2025.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G20, Rockville, MD 20892.

Meeting Format: Video Assisted Meeting.

Contact Person: Jennifer Hartt Meyers, Ph.D., Scientific Review Officer, Scientific Review Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G20, Rockville, MD 20892, 301–761–6602, jennifer.meyers@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: April 2, 2025.

Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2025–06007 Filed 4–7–25; 8:45 am]

BILLING CODE 4140–01–P